Heptares Therapeutics Company
Heptares Therapeutics develops novel, small-molecule drugs for G-protein-coupled receptors (GPCRs).
Founded Date:
2007
Investor Type:
N/A
Employee Number:
11-50
Investment Stage:
N/A
Funding Status:
M&A
Number Of Exists:
N/A
Technology:
Others
Industry:
PharmTech
Headquarters:
Welwyn Garden City, Hertford, United Kingdom
Estimated Revenue:
$10M to $50M